Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab across multiple cancer types in PD1 mRNA-defined tumors
2020-003022-22Phase 2Active
- Sponsor
- SOLTI
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of spartalizumab in cancer (2 cohorts), sponsored by SOLTI. Primary endpoint: Overall response rate. Started Feb 2021; status: active.
02
Drugs
spartalizumab
03
Conditions
cancer
Beyond the preview
Go deeper on 2020-003022-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003022-22.